{
  "id": "63f03939f36125a42600001b",
  "type": "summary",
  "question": "What is the use of darolutamide?",
  "ideal_answer": "Darolutamide is an approved treatment of non-metastatic, castration-resistant prostate cancer (also called nmCRPC).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34308608",
    "http://www.ncbi.nlm.nih.gov/pubmed/33830214",
    "http://www.ncbi.nlm.nih.gov/pubmed/35656777"
  ],
  "snippets": [
    {
      "text": "CONCLUSIONS: All three ARAT agents are efficacious options for the treatment of nmCRPC, whereas darolutamide appears to have the most favorable tolerability profile. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34308608",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: For nonmetastatic castration-resistant prostate cancer (nmCRPC), 3 drugs under patent protection-apalutamide, enzalutamide, and darolutamide-were approved based on randomized, placebo-controlled trials; 1 drug with generic availability, abiraterone acetate, showed efficacy in a single-arm trial and is commonly prescribed.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33830214",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: For nmCRPC, darolutamide offered optimal efficacy and safety among approved drugs, and abiraterone acetate may offer comparable metastasis-free survival benefit with cost savings from generic availability. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33830214",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35656777",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Darolutamide is an approved treatment for a different type of prostate cancer called non-metastatic, castration-resistant prostate cancer (also called nmCRPC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35656777",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}